WuXi Biologics a leading global CRDMO, announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 2022 hosted by IMAPAC. Over the years since 2017, it has received multiple awards in various categories at IMAPAC's events. APBCEA 2022 seeks to give recognition to exceptional CMO and CDMO that facilitate biologics manufacturing at enhanced speed, reduced cost, and superior quality from the biologics contract manufacturing space. The winners were determined through voting by more than 200 biopharma companies and service providers involved in biologics manufacturing in the APAC regions. WuXi Biologics won the "Best CDMO Award of the Year" with the highest number of votes in this category. Dr. Chris Chen, CEO of WuXi Biologics, said, "We are honored to be recognized by IMAPAC again. The 'Best CDMO Award of the Year' reflects the trust and confidence our customers have in us. As a valued CRDMO partner and enabler, WuXi Biologics is committed to providing the industry with end-to-end biologics solutions. We will continue to enable global partners by accelerating and transforming the discovery, development and manufacturing of innovative biologics, for the benefit of patients worldwide."